Chris Sullivan
InvestorChief Financial Officer at Avalo Therapeutics
About
CFO since February 2022 with strong public company and life sciences finance background. Previously served as Corporate Controller at Sucampo Pharmaceuticals (during its $1.2 billion merger with Mallinckrodt) and OpGen. Experienced in capital raises, M&A transactions, and enterprise resource planning in biotech and pharmaceutical sectors.
Colleagues at Avalo Therapeutics
Aaron Kantoff
Board Member at Avalo Therapeutics
Ashley Ivanowicz
Senior Vice President, Human Resources at Avalo Therapeutics
Colleen Matkowski
Senior Vice President, Global Regulatory Affairs and Quality Assurance at Avalo Therapeutics
Dino C. Miano
Senior Vice President, CMC and Technical Operations at Avalo Therapeutics
Garry A. Neil
Chief Executive Officer at Avalo Therapeutics
Gilla Kaplan
Board Member at Avalo Therapeutics
Jennifer Riley
Chief Strategy Officer at Avalo Therapeutics
Kathleen Cohen
Senior Vice President, Clinical Development Operations at Avalo Therapeutics
Frequently asked questions
- Who is Chris Sullivan?
- CFO since February 2022 with strong public company and life sciences finance background. Previously served as Corporate Controller at Sucampo Pharmaceuticals (during its $1.2 billion merger with Mallinckrodt) and OpGen. Experienced in capital raises, M&A transactions, and enterprise resource planning in biotech and pharmaceutical sectors.
- Where does Chris Sullivan work?
- Chris Sullivan is Chief Financial Officer at Avalo Therapeutics.